- Home
- MXE vs ACXP Comparison
MXE vs ACXP Comparison
Compare MXE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXE
- ACXP
- Stock Information
- Founded
- MXE 1990
- ACXP 2017
- Country
- MXE United States
- ACXP United States
- Employees
- MXE N/A
- ACXP N/A
- Industry
- MXE Finance Companies
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- MXE Finance
- ACXP Health Care
- Exchange
- MXE Nasdaq
- ACXP Nasdaq
- Market Cap
- MXE 45.0M
- ACXP 8.4M
- IPO Year
- MXE N/A
- ACXP 2021
- Fundamental
- Price
- MXE $10.87
- ACXP $0.49
- Analyst Decision
- MXE
- ACXP Strong Buy
- Analyst Count
- MXE 0
- ACXP 2
- Target Price
- MXE N/A
- ACXP $10.00
- AVG Volume (30 Days)
- MXE 5.8K
- ACXP 18.6M
- Earning Date
- MXE 01-01-0001
- ACXP 08-08-2025
- Dividend Yield
- MXE 2.66%
- ACXP N/A
- EPS Growth
- MXE N/A
- ACXP N/A
- EPS
- MXE N/A
- ACXP N/A
- Revenue
- MXE N/A
- ACXP N/A
- Revenue This Year
- MXE N/A
- ACXP N/A
- Revenue Next Year
- MXE N/A
- ACXP N/A
- P/E Ratio
- MXE N/A
- ACXP N/A
- Revenue Growth
- MXE N/A
- ACXP N/A
- 52 Week Low
- MXE $8.40
- ACXP $0.30
- 52 Week High
- MXE $11.51
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- MXE 74.94
- ACXP 51.01
- Support Level
- MXE $10.35
- ACXP $0.46
- Resistance Level
- MXE $10.58
- ACXP $0.56
- Average True Range (ATR)
- MXE 0.15
- ACXP 0.10
- MACD
- MXE 0.03
- ACXP -0.01
- Stochastic Oscillator
- MXE 90.48
- ACXP 24.27
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.